ICH ICH Enumeration: ShortName=Protocol Section Name and Number Response Terminology

M2 ESTRI Code List

ShortName = Protocol Section Name and Number Response Terminology
LongName = Protocol Section Name and Number Response Terminology
Version = 1.0
CanonicalUri = 2.16.840.1.113883.3.989.2.3.1.13
CanonicalVersionUri = 2.16.840.1.113883.3.989.2.3.1.13.1
Agency
ShortName = M11
LongName = Clinical Trial protocols
Identifier = C217272
code
Id="code"
(required)
Type="string"
english-label
Id="en"
(optional)
Type="string" Lang="en"
M11 Definition
Id="en_def"
(optional)
Type="string" Lang="en"
current flag
Id="cf"
(optional)
Type="string" Lang="en"
C218514 1 PROTOCOL SUMMARY Section 1 of the ICH M11 Protocol standard, PROTOCOL SUMMARY. y
C218515 1.1 Protocol Synopsis Section 1.1 of the ICH M11 Protocol standard, Protocol Synopsis. y
C218516 1.1.1 Primary and Secondary Objectives and Estimands Section 1.1.1 of the ICH M11 Protocol standard, Primary and Secondary Objectives and Estimands. y
C218517 1.1.2 Overall Design Section 1.1.2 of the ICH M11 Protocol standard, Overall Design. y
C218518 1.2 Trial Schema Section 1.2 of the ICH M11 Protocol standard, Trial Schema. y
C218519 1.3 Schedule of Activities Section 1.3 of the ICH M11 Protocol standard, Schedule of Activities. y
C218625 10 STATISTICAL CONSIDERATIONS Section 10 of the ICH M11 Protocol standard, STATISTICAL CONSIDERATIONS. y
C218626 10.1 General Considerations Section 10.1 of the ICH M11 Protocol standard, General Considerations. y
C218647 10.10 Multiplicity Adjustments Section 10.10 of the ICH M11 Protocol standard, Multiplicity Adjustments. y
C218648 10.11 Sample Size Determination Section 10.11 of the ICH M11 Protocol standard, Sample Size Determination. y
C218627 10.2 Analysis Sets Section 10.2 of the ICH M11 Protocol standard, Analysis Sets. y
C218628 10.3 Analyses of Demographics and Other Baseline Variables Section 10.3 of the ICH M11 Protocol standard, Analyses of Demographics and Other Baseline Variables. y
C218629 10.4 Analyses Associated with the Primary Objective(s) Section 10.4 of the ICH M11 Protocol standard, Analyses Associated with the Primary Objective(s). y
C218630 10.4.1 Primary Objective Section 10.4.1 of the ICH M11 Protocol standard, Primary Objective. y
C218631 10.4.1.1 Statistical Analysis Method Section 10.4.1.1 of the ICH M11 Protocol standard, Statistical Analysis Method. y
C218632 10.4.1.2 Handling of Data in Relation to Primary Estimand(s) Section 10.4.1.2 of the ICH M11 Protocol standard, Handling of Data in Relation to Primary Estimand(s). y
C218633 10.4.1.3 Handling of Missing Data in Relation to Primary Estimand(s) Section 10.4.1.3 of the ICH M11 Protocol standard, Handling of Missing Data in Relation to Primary Estimand(s) y
C218634 10.4.1.4 Sensitivity Analysis Section 10.4.1.4 of the ICH M11 Protocol standard, Sensitivity Analysis. y
C218635 10.4.1.5 Supplementary Analysis Section 10.4.1.5 of the ICH M11 Protocol standard, Supplementary Analysis. y
C218636 10.5 Analyses Associated with the Secondary Objective(s) Section 10.5 of the ICH M11 Protocol standard, Analyses Associated with the Secondary Objective(s). y
C218637 10.5.1 Secondary Objective Section 10.5.1 of the ICH M11 Protocol standard, Secondary Objective. y
C218638 10.5.1.1 Statistical Analysis Method Section 10.5.1.1 of the ICH M11 Protocol standard, Statistical Analysis Method. y
C218639 10.5.1.2 Handling of Data in Relation to Secondary Estimand(s) Section 10.5.1.2 of the ICH M11 Protocol standard, Handling of Data in Relation to Secondary Estimand(s). y
C218640 10.5.1.3 Handling of Missing Data in Relation to Secondary Estimand(s) Section 10.5.1.3 of the ICH M11 Protocol standard, Handling of Missing Data in Relation to Secondary Estimand(s). y
C218641 10.5.1.4 Sensitivity Analysis Section 10.5.1.4 of the ICH M11 Protocol standard, Sensitivity Analysis. y
C218642 10.5.1.5 Supplementary Analysis Section 10.5.1.5 of the ICH M11 Protocol standard, Supplementary Analysis. y
C218643 10.6 Analyses Associated with the Exploratory Objective(s) Section 10.6 of the ICH M11 Protocol standard, Analyses Associated with the Exploratory Objective(s). y
C218644 10.7 Safety Analyses Section 10.7 of the ICH M11 Protocol standard, Safety Analyses. y
C218645 10.8 Other Analyses Section 10.8 of the ICH M11 Protocol standard, Other Analyses. y
C218646 10.9 Interim Analyses Section 10.9 of the ICH M11 Protocol standard, Interim Analyses. y
C218649 11 TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS Section 11 of the ICH M11 Protocol standard, TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS. y
C218650 11.1 Regulatory and Ethical Considerations Section 11.1 of the ICH M11 Protocol standard, Regulatory and Ethical Considerations. y
C218663 11.10 Protocol Deviations Section 11.10 of the ICH M11 Protocol standard, Protocol Deviations. y
C218664 11.11 Early Site Closure Section 11.11 of the ICH M11 Protocol standard, Early Site Closure. y
C218665 11.12 Data Dissemination Section 11.12 of the ICH M11 Protocol standard, Data Dissemination. y
C218651 11.2 Trial Oversight Section 11.2 of the ICH M11 Protocol standard, Trial Oversight. y
C218652 11.2.1 Investigator Responsibilities Section 11.2.1 of the ICH M11 Protocol standard, Investigator Responsibilities. y
C218653 11.2.2 Sponsor Responsibilities Section 11.2.2 of the ICH M11 Protocol standard, Sponsor Responsibilities. y
C218654 11.3 Informed Consent Process Section 11.3 of the ICH M11 Protocol standard, Informed Consent Process. y
C218655 11.3.1 Informed Consent for Rescreening Section 11.3.1 of the ICH M11 Protocol standard, Informed Consent for Rescreening. y
C218656 11.3.2 Informed Consent for Use of Remaining Samples in Exploratory Research Section 11.3.2 of the ICH M11 Protocol standard, Informed Consent for Use of Remaining Samples in Exploratory Research. y
C218657 11.4 Committees Section 11.4 of the ICH M11 Protocol standard, Committees. y
C218658 11.5 Insurance and Indemnity Section 11.5 of the ICH M11 Protocol standard, Insurance and Indemnity. y
C218659 11.6 Risk-Based Quality Management Section 11.6 of the ICH M11 Protocol standard, Risk-Based Quality Management. y
C218660 11.7 Data Governance Section 11.7 of the ICH M11 Protocol standard, Data Governance. y
C218661 11.8 Data Protection Section 11.8 of the ICH M11 Protocol standard, Data Protection. y
C218662 11.9 Source Records Section 11.9 of the ICH M11 Protocol standard, Source Records. y
C218666 12 APPENDIX: SUPPORTING DETAILS Section 12 of the ICH M11 Protocol standard, APPENDIX: SUPPORTING DETAILS. y
C218667 12.1 Clinical Laboratory Tests Section 12.1 of the ICH M11 Protocol standard, Clinical Laboratory Tests. y
C218668 12.2 Country/Region-Specific Differences Section 12.2 of the ICH M11 Protocol standard, Country/Region-Specific Differences. y
C218669 12.3 Prior Protocol Amendment(s) Section 12.3 of the ICH M11 Protocol standard, Prior Protocol Amendment(s). y
C218670 13 APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS Section 13 of the ICH M11 Protocol standard, APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS. y
C218671 14 APPENDIX: REFERENCES Section 14 of the ICH M11 Protocol standard, APPENDIX: REFERENCES. y
C218520 2 INTRODUCTION Section 2 of the ICH M11 Protocol standard, INTRODUCTION. y
C218521 2.1 Purpose of Trial Section 2.1 of the ICH M11 Protocol standard, Purpose of Trial. y
C218522 2.2 Assessment of Risks and Benefits Section 2.2 of the ICH M11 Protocol standard, Assessment of Risks and Benefits. y
C218523 2.2.1 Risk Summary and Mitigation Strategy Section 2.2.2 of the ICH M11 Protocol standard, Risk Summary and Mitigation Strategy. y
C218524 2.2.2 Benefit Summary Section 2.2.1 of the ICH M11 Protocol standard, Benefit Summary. y
C218525 2.2.3 Overall Risk-Benefit Assessment Section 2.2.3 of the ICH M11 Protocol standard, Overall Risk-Benefit Assessment. y
C218526 3 TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS Section 3 of the ICH M11 Protocol standard, TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS. y
C218527 3.1 Primary Objective(s) and Associated Estimand(s) Section 3.1 of the ICH M11 Protocol standard, Primary Objective(s) and Associated Estimand(s). y
C218528 3.1.1 Primary Objective Section 3.1.1 of the ICH M11 Protocol standard, Primary Objective. y
C218529 3.2 Secondary Objective(s) and Associated Estimand(s) Section 3.2 of the ICH M11 Protocol standard, Secondary Objective(s) and Associated Estimand(s). y
C218530 3.2.1 Secondary Objective Section 3.2.1 of the ICH M11 Protocol standard, Secondary Objective. y
C218531 3.3 Exploratory Objective(s) Section 3.3 of the ICH M11 Protocol standard, Exploratory Objective(s). y
C218532 3.3.1 Exploratory Objective Section 3.3.1 of the ICH M11 Protocol standard, Exploratory Objective. y
C218533 4 TRIAL DESIGN Section 4 of the ICH M11 Protocol standard, TRIAL DESIGN. y
C218534 4.1 Description of Trial Design Section 4.1 of the ICH M11 Protocol standard, Description of Trial Design. y
C218535 4.1.1 Stakeholder Input into Design Section 4.1.1 of the ICH M11 Protocol standard, Stakeholder Input into Design. y
C218536 4.2 Rationale for Trial Design Section 4.2 of the ICH M11 Protocol standard, Rationale for Trial Design. y
C218537 4.2.1 Rationale for Estimand(s) Section 4.2.1 of the ICH M11 Protocol standard, Rationale for Estimand(s). y
C218538 4.2.2 Rationale for Intervention Model Section 4.2.2 of the ICH M11 Protocol standard, Rationale for Intervention Model. y
C218539 4.2.3 Rationale for Control Type Section 4.2.3 of the ICH M11 Protocol standard, Rationale for Control Type. y
C218540 4.2.4 Rationale for Trial Duration Section 4.2.4 of the ICH M11 Protocol standard, Rationale for Trial Duration. y
C218541 4.2.5 Rationale for Adaptive or Novel Trial Design Section 4.2.5 of the ICH M11 Protocol standard, Rationale for Adaptive or Novel Trial Design. y
C218542 4.2.6 Rationale for Interim Analysis Section 4.2.6 of the ICH M11 Protocol standard, Rationale for Interim Analysis. y
C218543 4.2.7 Rationale for Other Trial Design Aspects Section 4.2.7 of the ICH M11 Protocol standard, Rationale for Other Trial Design Aspects. y
C218544 4.3 Trial Stopping Rules Section 4.3 of the ICH M11 Protocol standard, Trial Stopping Rules. y
C218545 4.4 Start of Trial and End of Trial Section 4.4 of the ICH M11 Protocol standard, Start of Trial and End of Trial. y
C218546 4.5 Access to Trial Intervention After End of Trial Section 4.5 of the ICH M11 Protocol standard, Access to Trial Intervention After End of Trial. y
C218547 5 TRIAL POPULATION Section 5 of the ICH M11 Protocol standard, TRIAL POPULATION. y
C218548 5.1 Description of Trial Population and Rationale Section 5.1 of the ICH M11 Protocol standard, Description of Trial Population and Rationale. y
C218549 5.2 Inclusion Criteria Section 5.2 of the ICH M11 Protocol standard, Inclusion Criteria. y
C218550 5.3 Exclusion Criteria Section 5.3 of the ICH M11 Protocol standard, Exclusion Criteria. y
C218551 5.4 Contraception Section 5.4 of the ICH M11 Protocol standard, Contraception. y
C218552 5.4.1 Definitions Related to Childbearing Potential Section 5.4.1 of the ICH M11 Protocol standard, Definitions Related to Childbearing Potential. y
C218553 5.4.2 Contraception Requirements Section 5.4.2 of the ICH M11 Protocol standard, Contraception Requirements. y
C218554 5.5 Lifestyle Restrictions Section 5.5 of the ICH M11 Protocol standard, Lifestyle Restrictions. y
C218555 5.5.1 Meals and Dietary Restrictions Section 5.5.1 of the ICH M11 Protocol standard, Meals and Dietary Restrictions. y
C218556 5.5.2 Caffeine, Alcohol, Tobacco, and Other Restrictions Section 5.5.2 of the ICH M11 Protocol standard, Caffeine, Alcohol, Tobacco, and Other Restrictions. y
C218557 5.5.3 Physical Activity Restrictions Section 5.5.3 of the ICH M11 Protocol standard, Physical Activity Restrictions. y
C218558 5.5.4 Other Activity Restrictions Section 5.5.4 of the ICH M11 Protocol standard, Other Activity Restrictions. y
C218559 5.6 Screen Failure and Rescreening Section 5.6 of the ICH M11 Protocol standard, Screen Failure and Rescreening. y
C218560 6 TRIAL INTERVENTION AND CONCOMITANT THERAPY Section 6 of the ICH M11 Protocol standard, TRIAL INTERVENTION AND CONCOMITANT THERAPY. y
C218561 6.1 Description of Investigational Trial Intervention Section 6.1 of the ICH M11 Protocol standard, Description of Investigational Trial Intervention. y
C218580 6.10 Concomitant Therapy Section 6.10 of the ICH M10 Protocol standard, Concomitant Therapy. y
C218581 6.10.1 Prohibited Concomitant Therapy Section 6.10.1 of the ICH M10 Protocol standard, Prohibited Concomitant Therapy. y
C218582 6.10.2 Permitted Concomitant Therapy Section 6.10.2 of the ICH M10 Protocol standard, Permitted Concomitant Therapy. y
C218562 6.2 Rationale for Investigational Trial Intervention Dose and Regimen Section 6.2 of the ICH M11 Protocol standard, Rationale for Investigational Trial Intervention Dose and Regimen. y
C218563 6.3 Investigational Trial Intervention Administration Section 6.3 of the ICH M11 Protocol standard, Investigational Trial Intervention Administration. y
C218564 6.4 Investigational Trial Intervention Dose Modification Section 6.4 of the ICH M11 Protocol standard, Investigational Trial Intervention Dose Modification. y
C218565 6.5 Management of Investigational Trial Intervention Overdose Section 6.5 of the ICH M11 Protocol standard, Management of Investigational Trial Intervention Overdose. y
C218566 6.6 Preparation, Storage, Handling and Accountability of Investigational Trial Intervention Section 6.6 of the ICH M11 Protocol standard, Preparation, Storage, Handling and Accountability of Investigational Trial Intervention. y
C218567 6.6.1 Preparation of Investigational Trial Intervention Section 6.6.1 of the ICH M11 Protocol standard, Preparation of Investigational Trial Intervention. y
C218568 6.6.2 Storage and Handling of Investigational Trial Intervention Section 6.6.2 of the ICH M11 Protocol standard, Storage and Handling of Investigational Trial Intervention. y
C218569 6.6.3 Accountability of Investigational Trial Intervention Section 6.6.3 of the ICH M11 Protocol standard, Accountability of Investigational Trial Intervention. y
C218570 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding Section 6.7 of the ICH M11 Protocol standard, Investigational Trial Intervention Assignment, Randomisation and Blinding. y
C218571 6.7.1 Participant Assignment to Investigational Trial Intervention Section 6.7.1 of the ICH M11 Protocol standard, Participant Assignment to Investigational Trial Intervention. y
C218572 6.7.2 Randomisation Section 6.7.2 of the ICH M11 Protocol standard, Randomisation. y
C218573 6.7.3 Measures to Maintain Blinding Section 6.7.3 of the ICH M11 Protocol standard, Measures to Maintain Blinding. y
C218574 6.7.4 Emergency Unblinding at the Site Section 6.7.4 of the ICH M11 Protocol standard, Emergency Unblinding at the Site. y
C218575 6.8 Investigational Trial Intervention Adherence Section 6.8 of the ICH M11 Protocol standard, Investigational Trial Intervention Adherence. y
C218576 6.9 Description of Noninvestigational Trial Intervention Section 6.9 of the ICH M11 Protocol standard, Description of Noninvestigational Trial Intervention. y
C218577 6.9.1 Background Trial Intervention Section 6.9.1 of the ICH M11 Protocol standard, Background Trial Intervention. y
C218578 6.9.2 Rescue Therapy Section 6.9.2 of the ICH M11 Protocol standard, Rescue Therapy. y
C218579 6.9.3 Other Noninvestigational Trial Intervention Section 6.9.3 of the ICH M11 Protocol standard, Other Noninvestigational Trial Intervention. y
C218583 7 PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL Section 7 of the ICH M11 Protocol standard, PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL. y
C218584 7.1 Discontinuation of Trial Intervention for Individual Participants Section 7.1 of the ICH M11 Protocol standard, Discontinuation of Trial Intervention for Individual Participants. y
C218585 7.1.1 Permanent Discontinuation of Trial Intervention Section 7.1.1 of the ICH M11 Protocol standard, Permanent Discontinuation of Trial Intervention. y
C218586 7.1.2 Temporary Discontinuation of Trial Intervention Section 7.1.2 of the ICH M11 Protocol standard, Temporary Discontinuation of Trial Intervention. y
C218587 7.1.3 Rechallenge Section 7.1.3 of the ICH M11 Protocol standard, Rechallenge. y
C218588 7.2 Participant Discontinuation or Withdrawal from the Trial Section 7.2 of the ICH M11 Protocol standard, Participant Discontinuation or Withdrawal from the Trial. y
C218589 7.3 Management of Loss to Follow-Up Section 7.3 of the ICH M11 Protocol standard, Management of Loss to Follow-Up. y
C218590 8 TRIAL ASSESSMENTS AND PROCEDURES Section 8 of the ICH M11 Protocol standard, TRIAL ASSESSMENTS AND PROCEDURES. y
C218591 8.1 Trial Assessments and Procedures Considerations Section 8.1 of the ICH M11 Protocol standard, Trial Assessments and Procedures Considerations. y
C218592 8.2 Screening/Baseline Assessments and Procedures Section 8.2 of the ICH M11 Protocol standard, Screening/Baseline Assessments and Procedures. y
C218593 8.3 Efficacy Assessments and Procedures Section 8.3 of the ICH M11 Protocol standard, Efficacy Assessments and Procedures. y
C218594 8.4 Safety Assessments and Procedures Section 8.4 of the ICH M11 Protocol standard, Safety Assessments and Procedures. y
C218595 8.4.1 Physical Examination Section 8.4.1 of the ICH M11 Protocol standard, Physical Examination. y
C218596 8.4.2 Vital Signs Section 8.4.2 of the ICH M11 Protocol standard, Vital Signs. y
C218597 8.4.3 Electrocardiograms Section 8.4.3 of the ICH M11 Protocol standard, Electrocardiograms. y
C218598 8.4.4 Clinical Laboratory Assessments Section 8.4.4 of the ICH M11 Protocol standard, Clinical Laboratory Assessments. y
C218599 8.4.5 Pregnancy Testing Section 8.4.5 of the ICH M11 Protocol standard, Pregnancy Testing. y
C218600 8.4.6 Suicidal Ideation and Behaviour Risk Monitoring Section 8.4.6 of the ICH M11 Protocol standard, Suicidal Ideation and Behaviour Risk Monitoring. y
C218601 8.5 Pharmacokinetics Section 8.5 of the ICH M11 Protocol standard, Pharmacokinetics. y
C218602 8.6 Biomarkers Section 8.6 of the ICH M11 Protocol standard, Biomarkers. y
C218603 8.6.1 Genetics, Genomics, Pharmacogenetics and Pharmacogenomics Section 8.6.1 of the ICH M11 Protocol standard, Genetics, Genomics, Pharmacogenetics and Pharmacogenomics. y
C218604 8.6.2 Pharmacodynamic Biomarkers Section 8.6.2 of the ICH M11 Protocol standard, Pharmacodynamic Biomarkers. y
C218605 8.6.3 Other Biomarkers Section 8.6.3 of the ICH M11 Protocol standard, Other Biomarkers. y
C218606 8.7 Immunogenicity Assessments Section 8.7 of the ICH M11 Protocol standard, Immunogenicity Assessments. y
C218607 8.8 Medical Resource Utilisation and Health Economics Section 8.8 of the ICH M11 Protocol standard, Medical Resource Utilisation and Health Economics. y
C218608 9 ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION, AND SPECIAL SAFETY SITUATIONS Section 9 of the ICH M11 Protocol standard, ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION, AND SPECIAL SAFETY SITUATIONS. y
C218609 9.1 Definitions Section 9.1 of the ICH M11 Protocol standard, Definitions. y
C218610 9.1.1 Definitions of Adverse Events Section 9.1.1 of the ICH M11 Protocol standard, Definitions of Adverse Events. y
C218611 9.1.2 Definitions of Serious Adverse Events Section 9.1.2 of the ICH M11 Protocol standard, Definitions of Serious Adverse Events. y
C218612 9.1.3 Definitions of Product Complaints Section 9.1.3 of the ICH M11 Protocol standard, Definitions of Product Complaints. y
C218613 9.1.3.1 Definitions of Medical Device Product Complaints Section 9.1.3.1 of the ICH M11 Protocol standard, Definitions of Medical Device Product Complaints. y
C218614 9.2 Timing and Procedures for Collection and Reporting Section 9.2 of the ICH M11 Protocol standard, Timing and Procedures for Collection and Reporting. y
C218615 9.2.1 Timing Section 9.2.1 of the ICH M11 Protocol standard, Timing. y
C218616 9.2.2 Collection Procedures Section 9.2.2 of the ICH M11 Protocol standard, Collection Procedures. y
C218617 9.2.3 Reporting Section 9.2.3 of the ICH M11 Protocol standard, Reporting. y
C218618 9.2.3.1 Regulatory Reporting Requirements Section 9.2.3.1 of the ICH M11 Protocol standard, Regulatory Reporting Requirements. y
C218619 9.2.4 Adverse Events of Special Interest Section 9.2.4 of the ICH M11 Protocol standard, Adverse Events of Special Interest. y
C218620 9.2.5 Disease-related Events or Outcomes Not Qualifying as AEs or SAEs Section 9.2.5 of the ICH M11 Protocol standard, Disease-related Events or Outcomes Not Qualifying as AEs or SAEs. y
C218621 9.3 Pregnancy and Postpartum Information Section 9.3 of the ICH M11 Protocol standard, Pregnancy and Postpartum Information. y
C218622 9.3.1 Participants Who Become Pregnant During the Trial Section 9.3.1 of the ICH M11 Protocol standard, Participants Who Become Pregnant During the Trial. y
C218623 9.3.2 Participants Whose Partners Become Pregnant During the Trial Section 9.3.2 of the ICH M11 Protocol standard, Participants Whose Partners Become Pregnant During the Trial. y
C218624 9.4 Special Safety Situations Section 9.4 of the ICH M11 Protocol standard, Special Safety Situations. y
C222770 Amendment Details Amendment Details Section of the ICH M11 Protocol standard, Amendment Details. y
C222769 Title Page Title Page Section of the ICH M11 Protocol standard, Title Page. y

This file contains a code list co-maintained by ICH M2 ESTRI and CDISC in collaboration with the NCI Enterprise Vocabulary Services (EVS). It is encoded using OASIS genericode. More information on ICH technical standards is available via the M2 ESTRI webpages at www.ich.org.

Change History: v1.0 (November 11 2025)

Report created by ICH_M2_CDISC_Codelist.xsl : [Revision: 1.1 ] : ICH : Harmonisation for Better Health